SANTA ROSA, Calif., Oct. 29, 2017 /PRNewswire/ -- Millipede, Inc., a leader in device innovations for mitral and tricuspid disease, today announced the release of two peer-reviewed publications describing the use and efficacy of the transcatheter Millipede IRIS mitral annuloplasty ring. "We are pleased to see these initial clinical cases published," stated Randy Lashinski, Millipede's President and CEO.
These reports appear in the following journals: Structural Heart: The Journal of the Heart Team Transcatheter_Annuloplasty_for_Mitral_Regurgitation_with_an_Adjustable_Semi-Rigid_Complete_Ring_Initial_Experience_with_the_Millipede_IRIS_Device and in an upcoming issue of JACC Interventions - Combined MitraClip Edge-to-Edge Repair with Millipede IRIS Mitral Annuloplasty.
"I'm impressed with the performance of the latest Millipede IRIS system. The team at Millipede should be commended on continuously and rapidly-developing improvements to the implant and delivery catheter, focusing especially on its ease-of-use," noted Dr. Jason Rogers, the lead author on both publications.
Simultaneously, the ongoing series of Millipede mitral and tricuspid implants will be presented at TCT in Denver, October 29 to November 2, 2017. With this newly released clinical data of the Millipede IRIS in the mitral and tricuspid positions, patients have been followed over 22 months demonstrating virtual elimination of mitral regurgitation, without significant recurrence. These peer-reviewed publications describe the Millipede patients also having durable, favorable LV remodeling and clinical status. Millipede will continue additional clinical studies with its transcatheter delivery system and implant.
About Millipede, Inc.
Millipede, Inc. (www.millipedemedical.com) is a medical device company based in Santa Rosa, California with the goal of providing catheter delivery of the gold standard in heart valve repair – a complete annuloplasty ring.
SOURCE Millipede, Inc.